Phathom Pharmaceuticals Inc expected to post a loss of $1.04 a share - Earnings Preview

Phathom Pharmaceuticals

05/08/2025 14:32

Phathom Pharmaceuticals Inc PHAT.OQ PHAT.O is expected to  show a rise in quarterly revenue when it reports  results on August 7 for the period ending June 30 2025

The Florham Park New Jersey-based  company is expected to report a 392.6% increase in revenue to $36.077 million from $7.32 million a year ago, according to the mean estimate from 8 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Phathom Pharmaceuticals Inc is for a loss of $1.04 per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Phathom Pharmaceuticals Inc is $18.50, about 53.3% above its last closing price of $8.64

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-1.15
-1.15
-1.31
Missed
-14.2
Dec. 31 2025
-1.31
-1.27
-1.05
Beat
17.4
Sep. 30 2024
-1.59
-1.49
-1.32
Beat
11.7​
Jun. 30 2024
-1.40
-1.38
-1.56
Missed
-13
​​Mar. 31 2024
-1.28
-1.31
-1.42
Missed
-8.5
Dec. 31 2023
-1.10
-1.08
-1.39
Missed
-29.1​
Sep. 30 2023
-0.87
-0.89
-0.76
Beat
14.7
Jun. 30 2023
-0.94
-0.98
-0.84
Beat
14.2

This summary was machine generated August 5 at 13:32 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)